Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a corporate presentation on Tuesday, September 30, 2025, at 10:15 AM ET.
The virtual event will include a corporate presentation and one-on-one meetings with management. Investors interested in scheduling meetings can contact Lytham Partners directly or register through the conference website.
Positive
- None.
Negative
- None.
News Market Reaction 4 Alerts
On the day this news was published, RVPH declined 6.61%, reflecting a notable negative market reaction. Argus tracked a peak move of +9.8% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $28M at that time. Trading volume was elevated at 2.6x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.
Lytham Partners Fall 2025 Investor Conference
Format: Corporate Presentation and one-on-one meetings
Date: Tuesday, September 30, 2025
Time: 10:15 AM ET
Registration Link: Click Here
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at rvph@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Reviva Pharmaceuticals (RVPH) presenting at the Lytham Partners Fall 2025 Conference?
How can investors attend Reviva's (RVPH) presentation at the Lytham Partners Conference?
Who will be presenting for Reviva Pharmaceuticals at the Lytham Partners Conference?
How can investors schedule one-on-one meetings with Reviva's management?
